Neus Giménez, Alejandra Martínez-Trillos, Arnau Montraveta, Mónica Lopez-Guerra, Laia Rosich, Ferran Nadeu, Juan G. Valero, Marta Aymerich, Laura Magnano, Maria Rozman, Estella Matutes, Julio Delgado, Tycho Baumann, Eva Gine, Marcos González, Miguel Alcoceba, M. José Terol, Blanca Navarro, Enrique Colado, Angel R. Payer, Xose S. Puente, Carlos López-Otín, Armando Lopez-Guillermo, Elias Campo, Dolors Colomer, Neus Villamor. Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia. haematol [Internet]. 2019Feb.28 [cited 2024Apr.18];104(3):576-8. Available from: https://haematologica.org/article/view/8815